DIADEMA PARTNERS LP
Reported holdings as of Q2 2026, from 7 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ABIVAX SA OPT | ABVX | $101.8M | 163,644 | +7.67pp | 4q | +115.5%+$54.5M | |
| VIKING THERAPEUTICS INC OPT | VKTX | $78.5M | 441,808 | +3.37pp | 6q | -15.9%-$14.8M | |
| BRISTOL-MYERS SQUIBB CO OPT | BMY | $53.6M | options only | - | new | OPTIONS | |
| UNITED THERAPEUTICS CORP DEL | UTHR | $28.7M | 52,989 | -5.20pp | 3q | +94.1%+$13.9M | |
| REVOLUTION MEDICINES INC | RVMD | $26.1M | 139,218 | -0.12pp | 5q | +72.1%+$10.9M | |
| UNIQURE NV OPT | QURE | $24.6M | options only | +1.50pp | 7q | OPTIONS | |
| NOVARTIS AG OPT | NVS | $23.5M | options only | - | new | OPTIONS | |
| KODIAK SCIENCES INC OPT | KOD | $21.9M | 218,117 | -0.09pp | 4q | +13.0%+$2.5M | |
| CAPRICOR THERAPEUTICS INC OPT | CAPR | $20.8M | options only | -2.71pp | 7q | OPTIONS | |
| COGENT BIOSCIENCES INC | COGT | $19.1M | 493,664 | +0.30pp | 7q | +52.9%+$6.6M | |
| BRIDGEBIO PHARMA INC | $18.6M | 250,000 | -0.81pp | 2q | DEBT | ||
| CORCEPT THERAPEUTICS INC OPT | CORT | $17.9M | options only | +1.11pp | 6q | OPTIONS | |
| BIOMARIN PHARMACEUTICAL INC | BMRN | $17.9M | 312,846 | +0.84pp | 6q | +111.1%+$9.4M | |
| KYMERA THERAPEUTICS INC OPT | KYMR | $17.2M | options only | - | new | OPTIONS | |
| SUMMIT THERAPEUTICS INC OPT | SMMT | $16.3M | 60,000 | - | new | NEW | |
| HIMS & HERS HEALTH INC OPT | HIMS | $13.6M | options only | - | new | OPTIONS | |
| REPLIMUNE GROUP INC OPT | REPL | $13.3M | options only | +0.68pp | 7q | OPTIONS | |
| BIOGEN INC OPT | BIIB | $13.0M | options only | - | new | OPTIONS | |
| ELI LILLY & CO OPT | LLY | $12.0M | options only | +0.58pp | 6q | OPTIONS | |
| INCYTE CORP OPT | INCY | $11.9M | options only | -1.43pp | 4q | OPTIONS | |
| EDGEWISE THERAPEUTICS INC | EWTX | $11.1M | 272,214 | +0.26pp | 3q | HELD | |
| ARCUS BIOSCIENCES INC OPT | RCUS | $10.7M | 223,810 | +0.48pp | 2q | -6.0%-$686.7K | |
| BIONTECH SE OPT | BNTX | $9.3M | options only | - | new | OPTIONS | |
| CORBUS PHARMACEUTICALS HLDGS OPT | CRBP | $8.8M | 301,264 | +0.22pp | 2q | -31.5%-$4.0M | |
| VAXCYTE INC OPT | PCVX | $8.5M | 45,071 | +0.31pp | 7q | +79.8%+$3.8M | |
| BIOAGE LABS INC OPT | BIOA | $8.5M | 146,334 | +0.89pp | 3q | +143.9%+$5.0M | |
| IMMUNOCORE HLDGS PLC | IMCR | $8.1M | 254,863 | +0.03pp | 6q | +31.9%+$2.0M | |
| 4D MOLECULAR THERAPEUTICS IN | FDMT | $7.6M | 571,107 | - | new | NEW | |
| NOVO-NORDISK A S OPT | NVO | $7.5M | 100,000 | +0.51pp | 6q | +586.0%+$6.4M | |
| SELLAS LIFE SCIENCES GROUP I OPT | SLS | $7.4M | options only | +0.72pp | 5q | OPTIONS | |
| MODERNA INC OPT | MRNA | $7.0M | options only | -0.49pp | 2q | OPTIONS | |
| CORVUS PHARMACEUTICALS INC OPT | CRVS | $6.4M | 294,811 | -0.07pp | 4q | +20.4%+$1.1M | |
| MONTE ROSA THERAPEUTICS INC OPT | GLUE | $6.0M | 78,391 | +0.24pp | 3q | -58.1%-$8.4M | |
| ALUMIS INC OPT | ALMS | $5.6M | options only | +0.22pp | 2q | OPTIONS | |
| ROYALTY PHARMA PLC OPT | RPRX | $5.6M | options only | - | new | OPTIONS | |
| JOHNSON & JOHNSON | JNJ | $5.6M | 22,000 | -1.53pp | 3q | -59.1%-$8.1M | |
| UNICYCIVE THERAPEUTICS INC OPT | UNCY | $5.1M | 303,676 | +0.53pp | 2q | +186.3%+$3.3M | |
| CELLDEX THERAPEUTICS INC NEW OPT | CLDX | $5.1M | options only | - | new | OPTIONS | |
| BIOHAVEN LTD OPT | BHVN | $4.7M | options only | +0.14pp | 3q | OPTIONS | |
| VERA THERAPEUTICS INC OPT | VERA | $4.6M | 57,608 | - | new | NEW | |
| TENAX THERAPEUTICS INC OPT | TENX | $4.5M | options only | +0.08pp | 3q | OPTIONS | |
| RELAY THERAPEUTICS INC | RLAY | $4.3M | 230,677 | - | new | NEW | |
| TG THERAPEUTICS INC OPT | TGTX | $4.2M | options only | -0.64pp | 7q | OPTIONS | |
| AMGEN INC OPT | AMGN | $3.8M | 102,701 | - | new | NEW | |
| ZYMEWORKS INC | ZYME | $3.7M | 142,132 | -0.14pp | 6q | HELD | |
| TAYSHA GENE THERAPIES INC | TSHA | $3.6M | 522,619 | - | new | NEW | |
| INTELLIA THERAPEUTICS INC OPT | NTLA | $3.4M | options only | -0.01pp | 4q | OPTIONS | |
| NURIX THERAPEUTICS INC | NRIX | $2.9M | 121,539 | - | new | NEW | |
| INDIVIOR PHARMACEUTICALS INC | INDV | $2.8M | 67,512 | -0.02pp | 2q | -5.4%-$158.5K | |
| INVENTIVA SA | IVA | $2.7M | 740,786 | +0.02pp | 3q | +110.2%+$1.4M | |
| ORUKA THERAPEUTICS INC | ORKA | $2.6M | 27,799 | - | new | NEW | |
| CYTOKINETICS INC OPT | CYTK | $2.6M | options only | -2.48pp | 2q | OPTIONS | |
| RELMADA THERAPEUTICS INC | RLMD | $2.5M | 361,367 | +0.08pp | 3q | +79.9%+$1.1M | |
| ANNEXON INC OPT | ANNX | $2.2M | 27,516 | -0.18pp | 3q | -79.3%-$8.3M | |
| CELCUITY INC OPT | CELC | $2.1M | options only | -0.18pp | 2q | OPTIONS | |
| SEPTERNA INC OPT | SEPN | $2.0M | options only | +0.25pp | 2q | OPTIONS | |
| CYBIN INC OPT | HELP | $2.0M | 200,000 | - | new | NEW | |
| VOYAGER THERAPEUTICS INC OPT | VYGR | $2.0M | 413,642 | -0.13pp | 2q | -2.4%-$47.7K | |
| CONTINEUM THERAPEUTICS INC | CTNM | $2.0M | 119,733 | - | new | NEW | |
| BICYCLE THERAPEUTICS PLC | BCYC | $2.0M | 462,724 | -0.13pp | 2q | -2.9%-$58.1K | |
| VIRIDIAN THERAPEUTICS INC | VRDN | $1.8M | 100,000 | - | new | NEW | |
| MACROGENICS INC | MGNX | $1.7M | 374,403 | -0.08pp | 2q | -37.6%-$1.0M | |
| PROQR THRAPEUTICS N V | PRQR | $1.7M | 926,016 | +0.17pp | 7q | +414.2%+$1.4M | |
| ADMA BIOLOGICS INC OPT | ADMA | $1.7M | options only | - | new | OPTIONS | |
| SPRUCE BIOSCIENCES INC | SPRB | $1.6M | 30,000 | +0.09pp | 2q | +200.0%+$1.1M | |
| ARDELYX INC | ARDX | $1.5M | 303,025 | - | new | NEW | |
| CUE BIOPHARMA INC OPT | CUE | $1.5M | 48,369 | - | new | NEW | |
| MINERALYS THERAPEUTICS INC | MLYS | $1.5M | 56,347 | +0.07pp | 3q | +113.9%+$809.4K | |
| EYEPOINT INC OPT | EYPT | $1.5M | options only | -0.43pp | 2q | OPTIONS | |
| PROTHENA CORP PLC | PRTA | $1.5M | 149,482 | - | new | NEW | |
| PHATHOM PHARMACEUTICALS INC | PHAT | $1.4M | 129,950 | +0.07pp | 2q | +137.8%+$817.0K | |
| EVOLUS INC OPT | EOLS | $1.4M | options only | +0.09pp | 3q | OPTIONS | |
| SPYRE THERAPEUTICS INC | SYRE | $1.3M | 15,000 | - | new | NEW | |
| CORMEDIX INC OPT | CRMD | $1.3M | options only | -0.03pp | 4q | OPTIONS | |
| EDITAS MEDICINE INC OPT | EDIT | $1.3M | options only | - | new | OPTIONS | |
| EQUILLIUM INC | EQ | $1.3M | 400,282 | +0.01pp | 4q | -7.7%-$107.4K | |
| PYXIS ONCOLOGY INC OPT | PYXS | $1.2M | options only | - | new | OPTIONS | |
| XERIS BIOPHARMA HOLDINGS INC | XERS | $1.1M | 132,746 | flat | 4q | HELD | |
| PHARVARIS N V | PHVS | $1.0M | 29,321 | -0.01pp | 2q | HELD | |
| HARMONY BIOSCIENCES HLDGS IN | HRMY | $978.1K | 26,864 | -0.32pp | 4q | -71.1%-$2.4M | |
| CARTESIAN THERAPEUTICS INC | RNAC | $907.1K | 87,057 | - | new | NEW | |
| AQUESTIVE THERAPEUTICS INC OPT | AQST | $892.7K | options only | - | new | OPTIONS | |
| RIGEL PHARMACEUTICALS INC | RIGL | $892.6K | 22,816 | - | new | NEW | |
| ELICIO THERAPEUTICS INC OPT | ELTX | $829.3K | options only | - | new | OPTIONS | |
| PRECIGEN INC | PGEN | $771.2K | 135,293 | +0.06pp | 2q | +144.7%+$456.0K | |
| DEFINIUM THERAPEUTICS INC | DFTX | $726.8K | 15,451 | - | new | NEW | |
| PELTHOS THERAPEUTICS INC | PTHS | $700.1K | 24,773 | flat | 4q | HELD | |
| PEPGEN INC | PEPG | $671.9K | 373,284 | +0.04pp | 2q | +147.3%+$400.2K | |
| CG ONCOLOGY INC OPT | CGON | $518.7K | options only | - | new | OPTIONS | |
| ENLIVEN THERAPEUTICS INC | ELVN | $507.5K | 10,000 | +0.06pp | 2q | +3981.6%+$495.1K | |
| CONNECT BIOPHARMA HLDGS LTD | CNTB | $468.8K | 196,985 | -0.03pp | 2q | -1.8%-$8.8K | |
| LARIMAR THERAPEUTICS INC | LRMR | $447.2K | 146,637 | -0.07pp | 2q | -12.0%-$61.0K | |
| CELLECTAR BIOSCIENCES INC | CLRB | $384.6K | 138,341 | - | new | NEW | |
| FOGHORN THERAPEUTICS INC | FHTX | $326.5K | 66,908 | -0.02pp | 4q | -16.3%-$63.6K | |
| AYTU BIOPHARMA INC | AYTU | $319.4K | 148,546 | -0.12pp | 4q | -57.9%-$439.7K | |
| OCUGEN INC | OCGN | $306.0K | 200,000 | -0.12pp | 2q | HELD | |
| INOVIO PHARMACEUTICALS INC OPT | INO | $302.7K | options only | -0.15pp | 3q | OPTIONS | |
| UROGEN PHARMA LTD | URGN | $262.6K | 7,137 | -0.04pp | 7q | -69.2%-$589.5K | |
| HERON THERAPEUTICS INC | HRTX | $195.8K | 458,723 | - | new | NEW | |
| TALPHERA INC | TLPH | $158.2K | 153,563 | flat | 3q | HELD | |
| MONOPAR THERAPEUTICS INC | MNPR | $150.9K | 1,630 | flat | 2q | HELD | |
| LAKELAND INDS INC | LAKE | $150.8K | 14,108 | - | new | NEW | |
| UPSTREAM BIO INC | UPB | $132.1K | 19,093 | -0.02pp | 4q | -11.6%-$17.4K | |
| MEIRAGTX HLDGS PLC OPT | MGTX | $119.8K | 8,368 | - | new | NEW | |
| JATT II ACQUISITION CORP | $102.5K | 9,021 | - | new | NEW | ||
| KAILERA THERAPEUTICS INC | KLRA | $79.8K | 3,621 | - | new | NEW | |
| MANNKIND CORP | MNKD | $68.2K | 16,003 | -0.07pp | 6q | -91.4%-$726.8K | |
| ENTERA BIO LTD | ENTX | $41.2K | 23,260 | flat | 2q | HELD | |
| ARS PHARMACEUTICALS INC | SPRY | $38.9K | 4,860 | - | new | NEW | |
| APREA THERAPEUTICS INC | APRE | $36.0K | 44,907 | - | new | NEW | |
| TVARDI THERAPEUTICS INC | TVRD | $31.6K | 16,607 | - | new | NEW | |
| VISTAGEN THERAPEUTICS INC OPT | VTGN | $13.0K | options only | -0.01pp | 7q | OPTIONS | |
| NEXTCURE INC | NXTC | $12.4K | 7,742 | - | new | NEW | |
| ATYR PHARMA INC OPT | ATYR | $7.5K | options only | flat | 6q | OPTIONS | |
| JADE BIOSCIENCES INC OPT | JBIO | $3.2K | options only | flat | 4q | OPTIONS | |
| ERASCA INC OPT | ERAS | $1.8K | options only | - | new | OPTIONS |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $756.7M | 95.6% |
| Healthcare Services | $15.7M | 2.0% |
| Other sectors | $150.8K | 0.0% |
| Not classified | $18.8M | 2.4% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $791.3M | 116 | 43 | 21 | 32 | 38 | 50.4% | 45 |
| Q1 2026 | $587.7M | 111 | 44 | 24 | 19 | 52 | 50.5% | 45 |
| Q4 2025 | $580.5M | 119 | 46 | 16 | 23 | 33 | 49.4% | 48 |
| Q3 2025 | $391.0M | 106 | 53 | 6 | 22 | 22 | 39.1% | 45 |
| Q2 2025 | $328.2M | 75 | 23 | 16 | 15 | 20 | 53.7% | 45 |
| Q1 2025 | $383.3M | 72 | 31 | 17 | 10 | 45 | 67.5% | 45 |
| Q4 2024 | $233.1M | 86 | 0 | 0 | 0 | 0 | 51.8% | 45 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.